{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:01:13Z","timestamp":1785430873353,"version":"3.56.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T00:00:00Z","timestamp":1465776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T00:00:00Z","timestamp":1465776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/nm.4128","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T16:42:51Z","timestamp":1465836171000},"page":"735-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["Immunomodulatory drugs disrupt the cereblon\u2013CD147\u2013MCT1 axis to exert antitumor activity and teratogenicity"],"prefix":"10.1038","volume":"22","author":[{"given":"Ruth","family":"Eichner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Fern\u00e1ndez-S\u00e1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"van Bebber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Kathrin","family":"Garz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lemeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Rudelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca-Sabrina","family":"Targosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Knorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Slawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herrmann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Peschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Haass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina S","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Bassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,13]]},"reference":[{"key":"BFnm4128_CR1","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1056\/NEJM196212132672407","volume":"267","author":"GW Mellin","year":"1962","unstructured":"Mellin, G.W. & Katzenstein, M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N. Engl. J. Med. 267, 1238\u20131244 (1962).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4128_CR2","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/onc.2012.599","volume":"32","author":"J Shortt","year":"2013","unstructured":"Shortt, J., Hsu, A.K. & Johnstone, R.W. Thalidomide-analog biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 32, 4191\u20134202 (2013).","journal-title":"Oncogene"},{"key":"BFnm4128_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett, J.B., Dredge, K. & Dalgleish, A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4, 314\u2013322 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4128_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"BFnm4128_CR5","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu, Y.X. et al. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood 118, 4771\u20134779 (2011).","journal-title":"Blood"},{"key":"BFnm4128_CR6","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335 (2012).","journal-title":"Leukemia"},{"key":"BFnm4128_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.molcel.2007.06.001","volume":"26","author":"J Lee","year":"2007","unstructured":"Lee, J. & Zhou, P. DCAFs, the missing link of the CUL4\u2013DDB1 ubiquitin ligase. Mol. Cell 26, 775\u2013780 (2007).","journal-title":"Mol. Cell"},{"key":"BFnm4128_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nature05175","volume":"443","author":"S Angers","year":"2006","unstructured":"Angers, S. et al. Molecular architecture and assembly of the DDB1\u2013CUL4A ubiquitin ligase machinery. Nature 443, 590\u2013593 (2006).","journal-title":"Nature"},{"key":"BFnm4128_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer, E.S. et al. Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353 (2014).","journal-title":"Nature"},{"key":"BFnm4128_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain, P.P. et al. Structure of the human cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803\u2013809 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFnm4128_CR11","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1471-4159.2005.03344.x","volume":"94","author":"S Jo","year":"2005","unstructured":"Jo, S., Lee, K.H., Song, S., Jung, Y.K. & Park, C.S. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channels in rat brain. J. Neurochem. 94, 1212\u20131224 (2005).","journal-title":"J. Neurochem."},{"key":"BFnm4128_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.bbamcr.2011.01.005","volume":"1813","author":"KM Lee","year":"2011","unstructured":"Lee, K.M., Jo, S., Kim, H., Lee, J. & Park, C.S. Functional modulation of AMP-activated protein kinase by cereblon. Biochim. Biophys. Acta 1813, 448\u2013455 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnm4128_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.yexmp.2007.08.014","volume":"83","author":"KT Iacono","year":"2007","unstructured":"Iacono, K.T., Brown, A.L., Greene, M.I. & Saouaf, S.J. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp. Mol. Pathol. 83, 283\u2013295 (2007).","journal-title":"Exp. Mol. Pathol."},{"key":"BFnm4128_CR14","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","volume":"19","author":"P Kirk","year":"2000","unstructured":"Kirk, P. et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4, and facilitates their cell surface expression. EMBO J. 19, 3896\u20133904 (2000).","journal-title":"EMBO J."},{"key":"BFnm4128_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3579","volume":"13","author":"SK Parks","year":"2013","unstructured":"Parks, S.K., Chiche, J. & Pouyss\u00e9gur, J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat. Rev. Cancer 13, 611\u2013623 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4128_CR16","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.4161\/cc.26193","volume":"12","author":"DK Walters","year":"2013","unstructured":"Walters, D.K., Arendt, B.K. & Jelinek, D.F. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle 12, 3175\u20133183 (2013).","journal-title":"Cell Cycle"},{"key":"BFnm4128_CR17","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/leu.2012.91","volume":"26","author":"BK Arendt","year":"2012","unstructured":"Arendt, B.K. et al. Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia 26, 2286\u20132296 (2012).","journal-title":"Leukemia"},{"key":"BFnm4128_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nm.3867","volume":"21","author":"D Zhu","year":"2015","unstructured":"Zhu, D. et al. The cyclophilin A\u2013CD147 complex promotes the proliferation and homing of multiple-myeloma cells. Nat. Med. 21, 572\u2013580 (2015).","journal-title":"Nat. Med."},{"key":"BFnm4128_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple-myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"BFnm4128_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"BFnm4128_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A.K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. Br. J. Haematol. 164, 811\u2013821 (2014).","journal-title":"Br. J. Haematol."},{"key":"BFnm4128_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","volume":"124","author":"YX Zhu","year":"2014","unstructured":"Zhu, Y.X. et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124, 536\u2013545 (2014).","journal-title":"Blood"},{"key":"BFnm4128_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1-\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"BFnm4128_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold, G., Fischer, E.S. & Thom\u00e4, N.H. Structural basis of lenalidomide-induced CK1-\u03b1 degradation by the CRL4CRBN ubiquitin ligase. Nature 532, 127\u2013130 (2016).","journal-title":"Nature"},{"key":"BFnm4128_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","volume":"120","author":"M Chesi","year":"2012","unstructured":"Chesi, M. et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 120, 376\u2013385 (2012).","journal-title":"Blood"},{"key":"BFnm4128_CR26","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.1073\/pnas.96.12.6678","volume":"96","author":"CK Smith","year":"1999","unstructured":"Smith, C.K., Baker, T.A. & Sauer, R.T. Lon and Clp family proteases and chaperones share homologous substrate-recognition domains. Proc. Natl. Acad. Sci. USA 96, 6678\u20136682 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4128_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bjh.12622","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A.K. et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br. J. Haematol. 164, 233\u2013244 (2014).","journal-title":"Br. J. Haematol."},{"key":"BFnm4128_CR28","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1158\/0008-5472.CAN-04-3605","volume":"65","author":"Y Tang","year":"2005","unstructured":"Tang, Y. et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 65, 3193\u20133199 (2005).","journal-title":"Cancer Res."},{"key":"BFnm4128_CR29","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/sj.leu.2402894","volume":"17","author":"C Strupp","year":"2003","unstructured":"Strupp, C., Hildebrandt, B., Germing, U., Haas, R. & Gattermann, N. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 17, 1200\u20131202 (2003).","journal-title":"Leukemia"},{"key":"BFnm4128_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.leukres.2007.11.037","volume":"32","author":"C Kelaidi","year":"2008","unstructured":"Kelaidi, C. et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk. Res. 32, 1049\u20131053 (2008).","journal-title":"Leuk. Res."},{"key":"BFnm4128_CR31","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","volume":"118","author":"P Fenaux","year":"2011","unstructured":"Fenaux, P. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC-transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118, 3765\u20133776 (2011).","journal-title":"Blood"},{"key":"BFnm4128_CR32","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456\u20131465 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4128_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-013-1863-5","volume":"93","author":"A Giagounidis","year":"2014","unstructured":"Giagounidis, A. et al. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Ann. Hematol. 93, 1\u201311 (2014).","journal-title":"Ann. Hematol."},{"key":"BFnm4128_CR34","doi-asserted-by":"publisher","first-page":"12703","DOI":"10.1073\/pnas.1307684110","volume":"110","author":"C Mahony","year":"2013","unstructured":"Mahony, C. et al. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and non-neurotoxic in vitro. Proc. Natl. Acad. Sci. USA 110, 12703\u201312708 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4128_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbamcr.2013.02.028","volume":"1843","author":"F Bassermann","year":"2014","unstructured":"Bassermann, F., Eichner, R. & Pagano, M. The ubiquitin\u2013proteasome system\u2014implications for cell cycle control and the targeted treatment of cancer. Biochim. Biophys. Acta 1843, 150\u2013162 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnm4128_CR36","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar, S.K. et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 15, 1503\u20131512 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnm4128_CR37","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel, M. et al. Front-line transplantation program with lenalidomide, bortezomib and dexamethasone combination as induction and consolidation, followed by lenalidomide maintenance in patients with multiple myeloma: a phase 2 study by the Intergroupe Francophone du My\u00e9lome. J. Clin. Oncol. 32, 2712\u20132717 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnm4128_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson, P.G. et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116, 679\u2013686 (2010).","journal-title":"Blood"},{"key":"BFnm4128_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A.K. et al. Carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142\u2013152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4128_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood.V99.1.394","volume":"99","author":"JS Harrison","year":"2002","unstructured":"Harrison, J.S., Rameshwar, P., Chang, V. & Bandari, P. Oxygen saturation in the bone marrow of healthy volunteers. Blood 99, 394 (2002).","journal-title":"Blood"},{"key":"BFnm4128_CR41","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.4049\/jimmunol.171.4.1707","volume":"171","author":"G Staffler","year":"2003","unstructured":"Staffler, G. et al. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J. Immunol. 171, 1707\u20131714 (2003).","journal-title":"J. Immunol."},{"key":"BFnm4128_CR42","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/j.1582-4934.2010.01012.x","volume":"14","author":"J Hu","year":"2010","unstructured":"Hu, J. et al. Involvement of HAb18G\u2013CD147 in T cell activation and immunological synapse formation. J. Cell. Mol. Med. 14, 2132\u20132143 (2010).","journal-title":"J. Cell. Mol. Med."},{"key":"BFnm4128_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cellimm.2013.04.008","volume":"282","author":"J Landskron","year":"2013","unstructured":"Landskron, J. & Task\u00e9n, K. CD147 in regulatory T cells. Cell. Immunol. 282, 17\u201320 (2013).","journal-title":"Cell. Immunol."},{"key":"BFnm4128_CR44","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1182\/blood-2002-06-1774","volume":"101","author":"R Tehranchi","year":"2003","unstructured":"Tehranchi, R. et al. Granulocyte-colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101, 1080\u20131086 (2003).","journal-title":"Blood"},{"key":"BFnm4128_CR45","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1002\/pmic.200700038","volume":"7","author":"CJ Gloeckner","year":"2007","unstructured":"Gloeckner, C.J., Boldt, K., Schumacher, A., Roepman, R. & Ueffing, M. A novel tandem-affinity purification strategy for the efficient isolation and characterization of native protein complexes. Proteomics 7, 4228\u20134234 (2007).","journal-title":"Proteomics"},{"key":"BFnm4128_CR46","doi-asserted-by":"publisher","first-page":"16663","DOI":"10.1073\/pnas.1106123108","volume":"108","author":"R Le Floch","year":"2011","unstructured":"Le Floch, R. et al. CD147 subunit of lactate\u2013H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. USA 108, 16663\u201316668 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4128_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ng.2471","volume":"45","author":"K Birsoy","year":"2013","unstructured":"Birsoy, K. et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet. 45, 104\u2013108 (2013).","journal-title":"Nat. Genet."},{"key":"BFnm4128_CR48","doi-asserted-by":"publisher","first-page":"27148","DOI":"10.1074\/jbc.M112.388843","volume":"287","author":"YH Lo","year":"2012","unstructured":"Lo, Y.H., Ho, P.C. & Wang, S.C. Epidermal growth factor receptor protects proliferating cell nuclear antigen from cullin 4A protein-mediated proteolysis. J. Biol. Chem. 287, 27148\u201327157 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnm4128_CR49","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cell.2008.05.043","volume":"134","author":"F Bassermann","year":"2008","unstructured":"Bassermann, F. et al. The Cdc14B\u2013Cdh1\u2013Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134, 256\u2013267 (2008).","journal-title":"Cell"},{"key":"BFnm4128_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/ncb2651","volume":"15","author":"V Fern\u00e1ndez-S\u00e1iz","year":"2013","unstructured":"Fern\u00e1ndez-S\u00e1iz, V. et al. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2\/Tti1 degradation and promote survival in multiple myeloma. Nat. Cell Biol. 15, 72\u201381 (2013).","journal-title":"Nat. Cell Biol."},{"key":"BFnm4128_CR51","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.3740","volume":"20","author":"U Baumann","year":"2014","unstructured":"Baumann, U. et al. Disruption of the PRKCD\u2013FBXO25\u2013HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat. Med. 20, 1401\u20131409 (2014).","journal-title":"Nat. Med."},{"key":"BFnm4128_CR52","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1073\/pnas.1218311110","volume":"110","author":"B Schmid","year":"2013","unstructured":"Schmid, B. et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction and reduced motor neuron axon outgrowth. Proc. Natl. Acad. Sci. USA 110, 4986\u20134991 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4128_CR53","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ydbio.2004.02.026","volume":"270","author":"BN Kennedy","year":"2004","unstructured":"Kennedy, B.N. et al. Zebrafish rx3 and mab21l2 are required during eye morphogenesis. Dev. Biol. 270, 336\u2013349 (2004).","journal-title":"Dev. Biol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.4128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4128","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T22:57:40Z","timestamp":1684450660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.4128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,13]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFnm4128"],"URL":"https:\/\/doi.org\/10.1038\/nm.4128","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,13]]},"assertion":[{"value":"11 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.B. and K.S.G. received honoraria and research funding from Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}